Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters








Language
Year range
1.
China Pharmacy ; (12): 1500-1499, 2020.
Article in Chinese | WPRIM | ID: wpr-822372

ABSTRACT

OBJECTIVE:To evaluate guidelines f or health technology assessment (HTA)at home and abroad ,and to provide reference for scientific formulation of HTA guidelines in China. METHODS :Databases including PubMed ,Embase,Guidenlines International Network and 83 official websites from 26 countries governments and academic organizations were searched to collect HTA guidelines from inception to April 2020. Two reviewers independently screened literature and extracted data ,including basic characteristics, content of guideline and assessment content. Then a descriptive analysis was conducted. RESULTS & CONCLUSIONS:A total of 19 guidelines published during 2001 to 2018 were included ,7 guidelines(36.8%)were published in 2015-2020;in addition to 1 guideline from WHO ,14 guidelines (73.7%)were published in Europeand ,2 guidelines(10.5%) in North America and 1 guideline each from South America and Asia (5.3%). There were 11 guidelines(57.9%)developed by academic organizations and 8 guidelines(42.1%)by health administration ;11 guidelines(57.9%)were evidence-based ,while the others weren ’t evidence- based (42.1%). The purpose ,content and object of assessment are demonstrated in 19 guidelines;18 guidelines specified the assessment method (94.7%),and 16 guidelines(84.2%)defined the subject of assessment ;14 guidelines (73.7%)specified the HTA assessment process ;12 guidelines(63.3%)mentioned the conflict of interest in HTA assessment process;7 guidelines(36.8%)mentioned the application of assessment results. There are some differences in the formulation methods and contents of HTA guidelines in foreign countries ,but the core contents ar e basically the same. At present ,there is a lack of HTA guidelines in China. We can refer to foreign guidelines,and establish applicable HTA guidelines which aresuitable for national conditions ,so as to provide scientific guidance for HTA research.

2.
China Pharmacy ; (12): 125-130, 2019.
Article in Chinese | WPRIM | ID: wpr-816763

ABSTRACT

OBJECTIVE: To systematically evaluate the efficacy and safety of Clonidine tansdermal patch for child tic disorders in children, and to provide evidence-based reference for clinical treatment. METHODS: Retrieved from Medline, Embase, Cochrane library, CNKI, VIP, CBM and Wanfang database, randomized controlled trials (RCTs) about Clonidine tansdermal patch (trial group) versus other therapies (control group, including placebo group, thiopride group, haloperidol group) for child tic disorders were collected from datbase estallishment to July 2018. The literatures met inclusion criteria were summarized. After quality evaluation with Cochrane system evaluation manual 5.1.0, Meta-analysis of reduction rate (amount) of YGTSS, the incidence of ADR and response rate was performed by using Rev Man 5.3 statistical software. Descriptive analysis was performed on indicators of groups that were unable to perform Meta-analysis. RESULTS: A total of 8 RCTs involving 1 320 patients were included. Among them, 2 RCTs involved placebo in control group; 2 RCTs involved thiopride, 3 RCTs involved haloperidol, and 1 RCT involved thiopride and haloperidol. Results of Meta-analysis showed that reduction rate of YGTSS in trial group were significantly higher than haloperidol group [MD=21.94, 95%CI(21.03, 22.86), P<0.001], but there was no statistical significance compared with thiopride group [MD=10.66, 95%CI(-15.68, 37.00), P=0.43]. The incidence of adverse events (mainly including skin itching, redness, dry mouth, dizziness, decreased blood pressure, abnormal electrocardiogram) in trial group were significantly lower than thiopride group [OR=0.42, 95%CI(0.22, 0.82), P=0.01] and haloperidol group [OR=0.17, 95%CI(0.09, 0.32), P<0.001], but there was no statistical significance compared with placebo group [OR=0.61, 95%CI(0.29, 1.29), P=0.20]. There was no statistical significance in response rate of trial group compared with thiopride group [OR=1.29,95%CI(0.38, 4.39), P=0.69] and haloperidol group [OR=1.63, 95%CI(0.89, 2.96), P=0.11]. The results of descriptive analysis showed that reduction rate (amount) of YGTSS in trial group was significantly higher than that of placebo group (P<0.05), and response rate of trial group was significantly higher than that of placebo group (P<0.01). CONCLUSIONS: For child tic disorders in children, Clonidine tansdermal patch is better than placebo and haloperidol in reduction rate (amount) of YGTSS, and is similar to thiopride. Response rate of Clonidine tansdermal patch is better than that of placebo, and is similar to those of thiopride and haloperidol. The safety of Clonidine tansdermal patch is better than those of thiopride and haloperidol, and is similar to that of placebo.

3.
China Pharmacy ; (12): 4753-4758, 2017.
Article in Chinese | WPRIM | ID: wpr-663618

ABSTRACT

OBJECTIVE:To systematically evaluate the monitoring system for global short drugs,and provide evidence-based reference and policy recommendations for developing the short drug monitoring in China. METHODS:Relevant literatures pub-lished in PubMed,Embase,CNKI,Wanfang,VIP database from building to Apr. 3rd in 2017 were retrieved by using"Drugs (cheap drugs,essential medicines,emergency drugs) storage""Short drugs""Insufficient supply of drugs""Drug shortage"as Chinese keywords,and"Drug storage""Out-of-stock drug""Stortage of medicine""Stock out of medicine"as English keywords. Literatures about monitoring system for short drugs in Baidu,Google and national or regional health administration websites were collected,and general information,data collection,data validation,data reporting method,feedback and improvement measures of monitoring system were extracted. RESULTS & CONCLUSIONS:Totally 25 literatures were included,20 national or regional health administration websites were retrieved. 11 countries and European Union had established monitoring system for short drugs. The main reporting agencies in each country were different,which were production enterprises,business enterprises and medical in-stitutions. It was mainly reported by network. Data validation was mainly conducted by specialized departments or groups for short drugs in each country. The monitoring reporting included information of short drugs and discontinued drugs. Countermeasures in each country mainly included looking for alternative drugs,encouraging production,temporary import,looking for new or other sources of raw materials and speeding up the approval of short drugs. Besides, precautions included implementation relevant laws and guidelines for short drugs,and increasing the cooper-ation with non-government departments,etc. Monitoring sys-tem for short drugs needs to be further improved in China. Itis suggested to establish monitoring and early warning platform for short drugs,and hierarchical intervention mechanism,improv-ing relevant laws and developing guidelines on managing short drugs.

SELECTION OF CITATIONS
SEARCH DETAIL